🧐 ProPicks AI October update is out now! See which stocks made the listPick Stocks with AI

AveXis expands partnership with REGENXBIO; shares up 4%

Published 01/08/2018, 12:43 PM
© Reuters.  AveXis expands partnership with REGENXBIO; shares up 4%
RGNX
-
AVXS
-
  • AveXis (AVXS +3.5%) goes all in with REGENXBIO (RGNX -5.2%) by expanding its 2014 global license agreement focused on spinal muscular atrophy (SMA). Its lead candidate, AVXS-101, used REGENXBIO's NAV AAV9 vector.
  • Under the terms of the updated agreement, REGENXBIO grants AveXis exclusive global rights to all vectors in its NAV Technology Platform for the treatment of SMA in addition to amending certain terms. AveXis will pay $80M upfront, another $30M in a year, another $30M in two years, up to $120M in milestones and low double-digit royalties on net sales of all commercial SMA products using an NAV vector other than NAV AAV9.
  • Previously: AveXis volatile after update on lead candidate AVXS-101 (Jan. 5)
  • Now read: Featured Stocks In December's Dividend Growth Model Portfolio


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.